Shaun Foy

Shaun Foy is a highly experienced individual with a diverse background in the biotechnology and healthcare sectors. Shaun founded and served as the Executive Director of Econic Biosciences in 2022 and previously held the same position at Xap Therapeutics starting in 2020. Shaun also has extensive experience at ERS Genomics, where they served as Chairman from 2014 onwards and later took on the role of Founder and CEO.

Additionally, Shaun worked as a Venture Partner at S.R. One Ltd from 2017 to 2020 and as a Board Member at Accel-Rx - Canada's Health Science Accelerator from 2016 to 2020. Prior to that, they played a pivotal role at CRISPR Therapeutics as Founder and CBO/CFO, contributing to the development of gene-based medicines using the CRISPR/Cas9 gene-editing platform. Shaun also served as a Board Member at CRISPR Therapeutics and as an Independent Consultant, providing industry advisory services.

Before embarking on their entrepreneurial and executive roles, Shaun gained valuable experience at Nomura Phase4 Ventures, where they worked as a Partner and played a significant role in growth equity investments for emerging healthcare companies. Shaun was also part of the Healthcare Corporate Finance Group, assisting with corporate finance services and principal investments.

Overall, Shaun's work experience showcases their expertise in founding and leading successful biotechnology companies, providing strategic guidance, and contributing to advancements in gene-editing technologies.

Shaun Foy obtained their Bachelor of Science (hons) degree in Cell & Developmental Biology from The University of British Columbia. Shaun pursued further education and earned their Master of Science degree in Cell Biology & Immunology from the same institution. In 2006, Shaun obtained a certification as a Chartered Financial Analyst from the CFA Institute.